Patent ID: 11926668
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 19:
20. The method of claim 1, wherein the method further comprises administering to the patient an additional therapeutic agent, therapeutic regimen or procedure selected from cyclophosphamide, surgery, radiation, a cancer vaccine, a programmed death ligand 1 (PD-L1) inhibitor, a lymphocyte activation gene 3 (LAG3) inhibitor, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, an anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, a T-cell immunoglobulin and mucin containing −3 (TIM3) inhibitor, a B- and T-lymphocyte attenuator (BTLA) inhibitor, a T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor, a CD47 inhibitor, an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin-2 (Ang2) inhibitor, a transforming growth factor beta (TGFβ) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an antibody to a tumor-specific antigen, an anti-CD3/anti-CD20 bispecific antibody, a vaccine, granulocyte-macrophage colony-stimulating factor, a cytotoxin, an additional chemotherapeutic agent, an IL-6R inhibitor, an IL-4R inhibitor, an IL-10 inhibitor, a cytokine, a T-cell therapy, an antiinflammatory drug, non-steroidal anti-inflammatory drugs, and a dietary supplement.